BIOPHARMA INDUSTRY LEADER AMY SCHULMAN JOINS POLARIS PARTNERS

BIOPHARMA INDUSTRY LEADER AMY SCHULMAN JOINS POLARIS PARTNERS

Longtime Business Executive Assumes Role of Venture Partner and CEO of
Polaris-backed Arsia Therapeutics

BOSTON , MASS., July 29, 2014 (GLOBE NEWSWIRE) -- Polaris Partners today
announced the hiring of biopharmaceutical executive Amy Schulman as a Venture
Partner, based out of Boston. Schulman, who most recently served as General
Counsel, EVP, and Business Unit Lead of Pfizer Consumer Healthcare, will apply
decades of experience to the Polaris healthcare portfolio. She will also
assume the role of Chief Executive Officer of Arsia Therapeutics, an early
stage Polaris-backed company co-founded by Dr. Robert Langer and Polaris
Partner Alan Crane.

"Amy is a highly respected and uniquely talented leader who brings a diverse
and valuable skill set to our team and to our companies," said Terry McGuire,
Founding Partner of Polaris. "Her proven success in building global businesses
coupled with her energy and enthusiasm for the biotechnology space makes her
an ideal partner. We are looking forward to her contribution."

In addition to taking on the CEO role at Arsia, Schulman is expected to assume
a number of Polaris company board seats and continue to serve on the board of
Cambridge-based Alnylam (Nasdaq:ALNY). At Arsia, she will work closely with
Alan Crane who remains with the company as Chairman of the Board.

"We are thrilled to welcome Amy to the Polaris and Arsia families," said
Crane. "Her entrepreneurial spirit and deep understanding of the process for
drug development and commercialization will serve us all well. She is a
creative problem solver with acuity for execution, a highly valuable
combination which we know she will employ across a myriad of opportunities
with us."

At Pfizer, Schulman had a variety of executive roles including leading the
Nutrition business which was sold to Nestle for $11.85 billion and heading the
Consumer business which comprised well-known brands including Advil, ChapStick
and Emergen-C. She concurrently served as Pfizer General Counsel, managing a
team of 700 legal professionals while overseeing IP, regulatory, transactional
and litigation related matters. Schulman is currently a faculty member at
Harvard Business School where she serves as a senior lecturer. She is also the
recipient of numerous awards and accolades including Fortune's 50 Most
Powerful Women in Business 2013, The American Lawyer's Top 50 Innovators 2013,
and the Margaret Brent Women Lawyers Achievement Award from the American Bar
Association in 2012.

In choosing the next step in her professional career, Schulman continued to
place an emphasis on substance and culture:

"When I began connecting with the Polaris team, I was struck by the distinct
personalities of the individuals and the way in which the partnership
encourages different perspectives and points of view," said Schulman. "Clearly
the partners respect one another and their portfolio companies. I was drawn to
the firm's nurturing, long-term approach to innovation and company building
and now I'm proud to join the Polaris team."
About Amy Schulman

Amy W. Schulman is an accomplished business leader, widely recognized for
growing global businesses, demonstrating a commitment to people, and fostering
inclusive workplace cultures. In July, 2014, she joined Polaris Partners as a
Venture Partner and assumed the role of Chief Executive Officer of Arsia
Therapeutics, a Polaris-backed company. She also joined Harvard Business
School's Faculty, as a Senior Lecturer.

Prior to these roles, Schulman was responsible for leading Pfizer Inc.'s $4
billion Consumer Healthcare business, which operates in 90 countries and
includes well-known brands such as Advil, Centrum, and Chapstick. She also
served as Executive Vice President and General Counsel of Pfizer Inc.
Before joining Pfizer, Schulman was a partner at DLA Piper, where she was a
member of the Board and Executive Policy Committees, and built and led the
international law firm's mass tort and class-action practice.

Schulman has served as a visiting professor at Harvard and Yale Law Schools
and has been a guest lecturer at Harvard Business School and Tsinghua
University in Beijing, among others. A Phi Beta Kappa graduate of Wesleyan
University, Schulman earned her J.D. from Yale Law School in 1989. She serves
on the Board of Directors of The Brookings Institution and Wesleyan
University.
About Polaris Partners

Founded in 1996, Polaris Partners has more than $3.5 billion in capital under
management invested into a diverse portfolio of technology and healthcare
companies throughout their lifecycles. From the earliest startup phases
through the growth stages, Polaris Partners takes minority and majority
positions alongside outstanding management teams to help grow industry leading
companies. With offices in Boston, San Francisco and Dublin, Polaris partners
with an unparalleled network of repeat CEOs, entrepreneurs, top scientists and
emerging innovators who are positioned to make a significant impact in their
fields and vastly improve the way in which we all live and work. The result:
Hundreds of growing companies, thousands of jobs generated, and billions of
dollars of value created. For more information, visit:
www.polarispartners.com.

CONTACT: Emily Mendell, Polaris Partners, em@polarispartners.com, 781-522-6732

Polaris Partners Logo
 
Press spacebar to pause and continue. Press esc to stop.